86689.0006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: 1623

Examiner:

In re application of:

Victor Brantl

Serial No: 10/618,148

Filed: July 10, 2003

For: USE OF RIBOFURANOSE

DERIVATIVES AGAINST INFLAMMATORY BOWEL

DISEASES

NOV 2 6 2004 %

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed

Mail Stop AMENDMENT

Commissioner for Patents

P.O. Box 1450

Khare, Devesh

Alexandria, VA 22313-1450, on

November 22, 2004 Date of Deposit

Wei-Ning Yang, Reg. No. 38,690

Name Signature

11/22/2004

Date

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION (37 C.F.R. § 1.321(c))

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

IDENTIFICATION OF PERSON MAKING THIS DISCLAIMER

I, We	i-Ning Yang, represent	that I am	
	an applicant		
	an assignee		
XX	a representative authorized to sign on behalf of the assignee identified below owning all of the interest in this application.		
The assignee is:			
Name of assignee		RIBAPHARM PHARMACEUTICALS	
Address of assignee		3300 Hyland Avenue, Costa Mesa, California 92626	
Title of disclaimant authorized to sign on			
behalf of assignee		Attorney for Applicant/Patent Owner	

		RECORDAL OF ASSIGNMENT IN PATENT OFFICE
		The assignment was recorded on at
		Reel No.
		Frame No(s).
	XX	authorization for recordal of the assignment is to follow
		EXTENT OF INTEREST
	The e	xtent of my (our) interest is in
	XX	the whole of this invention
		a sectional interest in this invention as follows:
		DISCLAIMER
	t gran	PHARM PHARMACEUTICALS hereby disclaims the terminal part of a ted on the above-identified application, which would extend beyond the ate of the full statutory term of:
	XX	United States Patent No. 6,573,248 and 6,455,508 as presently shortened by any terminal disclaimer
		any patent granted on Application Serial No.
shall	be enf	agree that any patent so granted on the above-identified application forceable only for and during such period that the legal title to said be the same as the legal title to
	XX	United States Patent No. 6,573,248 and 6,455,508.
		any patent granted on Application Serial No.
this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.		

RIBAPHARM PHARMACEUTICALS does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of

	•
XX	United States Patent No. 6,573,248 and 6,455,508 as presently shortened by any terminal disclaimer
	any patent granted on Application Serial No
unenforceat disclaimed certificate,	It that it later: expires for failure to pay a maintenance fee, is held ble, is found invalid, is statutorily disclaimed in whole or terminally under 37 C.F.R. §1.321(a), has all claims cancelled by a reexamination or is otherwise terminated prior to expiration of its statutory term as nortened by any terminal disclaimer, except for the separation of legal above.
	FEE STATUS
	(37 C.F.R. § 1.20(d))
XX	Other than small entity
	Small entity
	☐ verified statement attached
	verified statement filed
	FEE PAYMENT
	Attached is a check in the sum of \$
	If it should be determined that for any reason either an insufficient fee or an excessive fee has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. A copy of this petition is enclosed.

Undersigned further declares that the evidentiary documents establishing ownership by the assignee have been reviewed and certifies that to the best of assignee's knowledge and belief, title is in the assignee seeking to take this action.

Charge Account No. 50-1314 the sum of \$110.00. A duplicate of this

XX

disclaimer is attached.

Undersigned further declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: November 22, 2004

Wei-Ning Yang

Reg. No. 38,690

Attorney for Applicant and Assignee

HOGAN & HARTSON L.L.P. Biltmore Tower 500 South Grand Avenue, Suite 1900 Los Angeles, CA 90071

Telephone: (213) 337-6700 Facsimile: (213) 337-6701

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Art Unit: 1623

Victor Brantl

Examiner: Khare, Devesh

Serial No: 10/618,148

Filed: July 10, 2003

USE OF RIBOFURANOSE

DERIVATIVES AGAINST INFLAMMATORY BOWEL

DISEASES

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed

Mail Stop AMENDMENT Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450, on

November 22, 2004 **Date of Deposit**

Wei-Ning Yang, Reg. No. 38,690

Name

Signature

Date

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION (37 C.F.R. § 1.321(c))

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

IDENTIFICATION OF PERSON MAKING THIS DISCLAIMER

I, Wei-Ning Yang, repres	sent that I am		
an applicant	an applicant		
an assignee	an assignee		
-	a representative authorized to sign on behalf of the assignee identified below owning all of the interest in this application.		
The assignee is:			
Name of assignee	RIBAPHARM PHARMACEUTICALS		
Address of assignee	3300 Hyland Avenue, Costa Mesa, California 92626		
Title of disclaimant authorized to sign on			
behalf of assignee	Attorney for Applicant/Patent Owner		

		RECORDAL OF ASSIGNMENT IN PATENT OFFICE
1		The assignment was recorded on at
		Reel No.
		Frame No(s).
:	XX	authorization for recordal of the assignment is to follow
		EXTENT OF INTEREST
1	The ex	stent of my (our) interest is in
	XX	the whole of this invention
		a sectional interest in this invention as follows:
		DISCLAIMER
patent	grant	PHARM PHARMACEUTICALS hereby disclaims the terminal part of a ed on the above-identified application, which would extend beyond the ate of the full statutory term of:
	XX	United States Patent No. 6,573,248 and 6,455,508 as presently shortened by any terminal disclaimer
		any patent granted on Application Serial No.
shall b	oe enf	agree that any patent so granted on the above-identified application orceable only for and during such period that the legal title to said be the same as the legal title to
	XX	United States Patent No. 6,573,248 and 6,455,508.
		any patent granted on Application Serial No
		ent to run with any patent granted on the above-identified application ding upon the grantor, its successors or assigns.

RIBAPHARM PHARMACEUTICALS does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of

	•
XX	United States Patent No. 6,573,248 and 6,455,508 as present shortened by any terminal disclaimer
	any patent granted on Application Serial No
unenforceab disclaimed u certificate, o	It that it later: expires for failure to pay a maintenance fee, is helple, is found invalid, is statutorily disclaimed in whole or terminally under 37 C.F.R. §1.321(a), has all claims cancelled by a reexamination or is otherwise terminated prior to expiration of its statutory term a nortened by any terminal disclaimer, except for the separation of legal above.

FEE STATUS

(37 C.F.R. § 1.20(d))

XX	Other than small entity
	Small entity
	verified statement attached
	verified statement filed
	FEE PAYMENT
	Attached is a check in the sum of \$
	If it should be determined that for any reason either an insufficient fee or an excessive fee has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. A copy of this petition is enclosed.
XX	Charge Account No. 50-1314 the sum of \$110.00. A duplicate of this disclaimer is attached.

Undersigned further declares that the evidentiary documents establishing ownership by the assignee have been reviewed and certifies that to the best of assignee's knowledge and belief, title is in the assignee seeking to take this action.

Undersigned further declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: November 22, 2004

Wei-Ning Yang Reg. No. 38,690

Attorney for Applicant and Assignee

HOGAN & HARTSON L.L.P. Biltmore Tower 500 South Grand Avenue, Suite 1900

Los Angeles, CA 90071

Telephone: (213) 337-6700 Facsimile: (213) 337-6701